Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Cartalax peptide: Metabolic / Longevity research guide

In short: Cartalax (Ala-Glu-Asp / AED) is a synthetic short-peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell cultures. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use, not for human or clinical use.

Not medical advice. Cartalax is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

Cartalax at a glance

Compound type

Research peptide

Research category

Metabolic / Longevity

Also known as

Cartalax, AED, Ala-Glu-Asp, Alanyl-Glutamyl-Aspartate, Khavinson cartilage bioregulator, AED tripeptide, connective-tissue peptide bioregulator

Molecular weight

333.30 Da

Research-grade purity

99.31% HPLC

Evidence context

Preclinical / research use only

Regulatory status

Not an approved medicine. Supplied as a research compound

Last reviewed

26 June 2026

What to know first

Compound Cartalax Research class Metabolic / Longevity Catalog code Car20 Purity 99.31% HPLC Available pack sizes 10 × 20 mg Storage Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation.

Details and limits sit in the sections below. Research use only. No unsupported scientific claims are added here.

What Cartalax is

Cartalax (Ala-Glu-Asp, "AED") is a three-amino-acid peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell models.

One-paragraph overview from our research datasheet. Still scientific, but faster to read than the full mechanism list below.

Cartalax (Ala-Glu-Asp / AED) is a synthetic short-peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell cultures.

Research contexts

Peer-reviewed papers discuss Cartalax in specific lab settings. The points below reflect research questions, not health claims.

Research vs. personal use: Literature describes experiments in cells and animals. That is distinct from real-world use. Our products are for laboratory research only.

Typical study contexts

Mitochondrial stress, NAD+/redox biology and nutrient-sensing pathways.

Enzyme activity, gene expression or endurance-style animal readouts.

Synthetic Ala-Glu-Asp (AED) tripeptide from the Khavinson short-peptide bioregulator lineage.

Studied as a tissue-specific transcriptional modulator in connective-tissue and cartilage cell cultures.

Investigated for effects on chondrocyte and fibroblast proliferation in ageing-tissue models.

Examined for modulation of matrix-remodelling and pro-inflammatory signalling markers in vitro.

Why Metabolic / Longevity research matters

Researchers study these compounds for mitochondrial function and cellular energy stress. Ageing and metabolic disease models are common.

Mechanisms (technical review)

Our datasheet lists mechanistic themes from preclinical work. These are research endpoints, not health claims.

Synthetic Ala-Glu-Asp (AED) tripeptide from the Khavinson short-peptide bioregulator lineage

Studied as a tissue-specific transcriptional modulator in connective-tissue and cartilage cell cultures

Investigated for effects on chondrocyte and fibroblast proliferation in ageing-tissue models

Examined for modulation of matrix-remodelling and pro-inflammatory signalling markers in vitro

Belongs to the same "cytogen" peptide family as Epitalon (AEDG) and Vesugen (KED)

Small, defined tripeptide structure - high reproducibility as a research reference compound

Lab handling & preparation

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation.. See the storage guide.

Research dosing context: Literature typically discusses 1–10 mg subcutaneous injection (research-protocol range). Once daily in short pulsed cycles (e.g. 10–20 days), mirroring published cytogen-peptide schedules Formal human pharmacokinetic parameters (t½, Vd, bioavailability) have not been published for Cartalax. As a tripeptide (MW 333.30 Da) it is subject to rapid peptidase hydrolysis releasing its constituent amino acids. Subcutaneous and intraperitoneal routes are standard in the published short-peptide literature; oral bioavailability is not characterised. These figures describe the research literature and are not a dosing recommendation.

Preparation: Follow the reconstitution guide. Confirm volumes with the calculator.

Purity check: Use the COA reading guide and the published Cartalax Certificate of Analysis.

Common Questions People Are Asking

What is Cartalax used for in research?

Cartalax (Ala-Glu-Asp / AED) is studied as a tissue-specific short-peptide bioregulator focused on cartilage and connective tissue. Research has examined its influence on chondrocyte and fibroblast proliferation and on gene-expression markers tied to connective-tissue ageing, mostly in cell-culture and animal models.

What does "AED" mean and how is Cartalax related to Epitalon?

AED is the one-letter code for the sequence Alanine-Glutamate-Aspartate - the three amino acids that make up Cartalax. It belongs to the same Khavinson "cytogen" peptide family as Epitalon (AEDG, four residues) and Vesugen (KED). They share a common design idea - very short peptides acting as tissue-specific gene regulators - but each is matched to a different tissue, with Cartalax assigned to cartilage / connective tissue.

How is Cartalax proposed to work?

The Khavinson bioregulator model proposes that short peptides like Cartalax are small enough to enter the cell nucleus, bind specific promoter sequences in DNA, and modulate the transcription of genes in their target tissue. For Cartalax that target is connective tissue. This is a research hypothesis supported by in-vitro and animal data rather than established human pharmacology.

Is there human clinical data for Cartalax?

No controlled human pharmacokinetic or efficacy data for Cartalax specifically has been published. Most of the evidence comes from cell-culture and animal studies on the short-peptide bioregulator family. It remains a research compound, not a validated therapy, and is sold here strictly for laboratory use.

How should Cartalax be stored?

Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water or sterile saline, refrigerate at 1–6 °C and protect from light. As a small, simple tripeptide it tolerates standard peptide-handling conditions well within the normal usage window.

Is this page medical advice? Can I use Cartalax for my health?

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Where do I find Cartalax specs, purity certificates and pricing?

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

Related peptide guides

Other compounds researchers often read about alongside Cartalax.

Epitalon: Metabolic / Longevity research guide

MOTS-C: Metabolic / Longevity research guide

5-Amino-1MQ: Metabolic / Longevity research guide

FOXO4-DRI: Metabolic / Longevity research guide

SS-31: Metabolic / Longevity research guide

Continue Cartalax research

Analytical evidence, comparisons and current research for this compound. Research use only.

Analytical evidence View the Cartalax COA Current batch purity and identity testing, 2026-06-23. View the COA →

Research area Cognitive & longevity research The neuropeptide and longevity research area - nootropic and geroprotective peptides and related compounds studied in cognition… Explore the research area →

Scientific sources & further reading

Primary literature and registries for Cartalax, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

PubMed: peer-reviewed literature on Cartalax

ClinicalTrials.gov: registered studies on Cartalax

Cartalax: Wikipedia (search)

Peptides in the news:

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Ready to order? View full product specs

Access concentration, batch info, variants, and current pricing on our shop.

Also known as: Cartalax, AED, Ala-Glu-Asp, Alanyl-Glutamyl-Aspartate, Khavinson cartilage bioregulator, AED tripeptide, connective-tissue peptide bioregulator

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research